Market Currents
Genzyme (GENZ) will try to convince shareholders today that its Campath drug could reach annual...
-
Monday, December 20, 2010, 8:56 AM ETGenzyme (GENZ) will try to convince shareholders today that its Campath drug could reach annual sales of $3.5B, not the $700M forecast by Sanofi (SNY). The Campath valuation is the driving force behind Genzyme's claim that Sanofi needs to raise its $69/share offer.
Other date
Latest Articles
